Echocardiographic Imaging of Coronary Sinus Diverticula and Middle Cardiac Veins in Patients with Preexcitation Syndrome: Impact on Radiofrequency Catheter Ablation of Posteroseptal Accessory Pathways

OMRAN, H., ^{et al}.: Echocardiographic Imaging of Coronary Sinus Diverticula and Middle Cardiac Veins in Patients with Preexcitation Syndrome: Impact on Radiofrequency Catheter Ablation of Posteroseptal Accessory Pathways . To determine the value of echocardiography for identifying coronary sinus (CS) diverticula and middle cardiac veins (MCVs) in patients with posteroseptal accessory pathways (PAPs), transthoracic (TTE) and transesophageal echocardiography (TEE) were performed in 18 consecutive patients with PAP and in 15 control subjects with left lateral accessory pathway before CS angiography. The size, shape, and location of CS diverticula and MCV were described and compared to angiography. TEE and angiography were concordant for the identification of diverticula (n = 5) and agreed for depicting MCV in 22 of the 27 cases. TTE revealed 4 of 5 diverticula and identified 4 of 27 MCV (P < 0.001). Fourteen MCV but no diverticula were found in the control subjects. There was no significant difference between transesophageal and angiographic measurements for the width (23.5 ± 4.9 vs 26.8 ± 6.6 mm) and height (13.5 ± 3.8 vs 15.7 ± 3.4 mm) of the diverticula, and the width (3.5 ± 0.7 vs 3.7 ± 0.6 mm) of MCV. TEE underestimated the length of the MCV (12.0 ± 1.8 vs 27.2 ± 6.0, P < 0.001). Delivery of radiofrequency energy within the neck of a diverticulum or within an MCV was successful in 5 of 5, and 6 of 13 cases in patients with PAPs, respectively. In conclusion, echocardiography was as reliable as angiography for detecting and describing CS diverticula and MCV in patients with preexcitation syndrome. Echocardiography is recommended prior to electrophysiological study because it may simplify radiofrequency catheter ablation.     

A Prospective Randomized Evaluation of VV Delay Optimization in CRT-D Recipients: Echocardiographic Observations from the RHYTHM II ICD Study

Background: All current cardiac resynchronization therapy (CRT) devices allow the programming of the atrioventricular (AV/PV) delays and the sequential stimulation of the ventricles via the inter ventricular (VV) delay.
Aim: This post hoc analysis of the RHYTHM II study was conducted to compare the reverse remodeling associated with VV delay optimization in patients randomly assigned to simultaneous (SIM) biventricular stimulation versus patients assigned to optimized VV delay programming (OPT) (1:3 randomization scheme).
Methods: The analysis included 14 patients assigned to the SIM group and 34 patients to the OPT group who completed the 6-month follow-up period with paired echocardiographic recordings.
Results: In both study groups, changes consistent with left ventricular (LV) remodeling were observed between baseline and 6 months, with significant improvements in LV function and decrease in LV dimensions. In the OPT group, there was also a decrease in left atrial diameter and mitral valve closure to opening time. At 6 months, the overall proportion of echocardiographic responders (≥10% decrease in LV end-systolic volume or ≥5% absolute increase in LV ejection fraction) was similar in both groups. The optimal AV/VV delays, evaluated by maximization of LV outflow tract velocity time integral, changed over time.
Conclusions: Ventriculo-ventricular delay optimization was associated with better immediate hemodynamic function than simultaneous biventricular stimulation, though did not promote additional reverse remodeling at 6 months and did not increase the proportion of echocardiographic responders to CRT. Optimization of both the AV and VV intervals was patient-specific and optimal values changed over time.     

How Can We Identify the Best Implantation Site for an ECG Event Recorder?

ZELLERHOFF, C., et al. : How Can We Identify the Best Implantation Site for an ECG Event Recorder? The aim of this study was to show how to find the preferable implantation site for an ECG event recorder (ECG‐ER). We compared the quality of bipolar ECG recordings (4‐cm electrode distance, vertical position) in 65 patients at the following sites: left and right subclavicular, left and right anterior axillary line (4th‐5th interspace), left and right of the sternum (4th‐5th interspace), heart apex, and subxyphoidal. The results were compared to the standard ECG lead II. In 30 patients, an additional comparison between vertical and horizontal ECG registrations was done using the same sites. ECG signals in five patients were compared positioning the electrodes towards the skin with turning them towards the muscle during ECG‐ER implantation. The best ECG quality (defined as highest QRS amplitude, best visible P wave and/or pacemaker spike, best measurable QRS duration, and QT interval) and best agreement with the standard lead II was found in 68% on the left of the sternum, significantly less often (P < 0.001 ) on the right of the sternum (14.1%), left subclavicular (6.9%), apical (5.5%) and subxyphoidal (4.2%). A significantly higher QRS amplitude was measured and the P wave was more often visible in the vertical electrode position than in the horizontal position. In all five ECG‐ER patients, there was a good agreement between the bipolar surface ECG at the implantation site and ECG‐ER stored signals. A significant noise signal occurred in all five patients when the ECG‐ER was implanted with electrodes towards the muscle. A P wave was visible in only three of those patients, but there was an insignificantly higher QRS amplitude than in ECG‐ERs implanted with electrodes towards the skin. From these results, it can be concluded that the best implantation site for an ECG‐ER is right or left of the sternum, positioning the electrodes vertically and towards the skin.     

Holter Recordings with Continuous Marker Annotations: A New Tool in Pacemaker Diagnostics

Pacemakers provide marker annotations to facilitate the interpretation of pacemaker electrocardiograms (ECGs) and can be used in cases of suspected pacemaker malfunction or to understand pacemaker behavior. Due to the need for a programmer, only short-term evaluations are possible. We evaluated a prototype Telemetry Data Logger (TDL) designed to continuously transfer markers from the pacemaker to a conventional Holter recorder. A miniaturized telemetry receiving coil was attached to patient's skin above the pacemaker, which was programmed to transmit markers continuously. The TDL, which receives and converts markers into eight positive and eight negative deflections, ranging from -2.5 to +2.5 mV in amplitude, was connected to one channel of a conventional Holter recorder (Tracker 2). We performed 20 Holters in 13 patients who had implanted VDDB or DDDR devices from the same manufacturer and evaluated three versions of software. Marker transmission was possible in all patients, producing Holter ECGs with complete marker annotations. Artifacts occurred < 4 % of the time. A 50-ms rectangular pulse was optimal for marker interpretation. The device, which was easy to use and well accepted by the patients, assisted in the diagnosis of inappropriate pacemaker programming, even when the surface ECG seemed to show regular pacemaker function. In the presence of low quality surface ECGs, marker annotations allowed the assessment of pacemaker function. The capability to annotate the onset of special algorithms, like tachycardia termination algorithms or mode switching, facilitates interpretation of pacemaker behavior, enabling a reliable assessment of the appropriateness of such algorithms. Conclusion: The TDL effectively enables pacemaker markers to be inscribed onto a conventional Holter recording, facilitating the interpretation of pacemaker ECGs and the diagnosis of inappropriate pacemaker programming even when not discernible from the surface ECG alone.     

Defibrillator Implantation in a Patient with a Persistent Left Superior Vena Cava

The implantation of a transvenous cardioverter defibrillator (PCD 7217B) was performed in a patient with a persistent left superior vena cava. The defibrillation electrodes were positioned in the right ventricle and the superior vena cava via the right subclavian vein. A subcutaneous patch had to be implanted at the left lateral chest wall to achieve sufficient defibrillation thresholds. Three weeks later the system had to be removed because of a generator pocket infection. During the second implantation we placed one electrode in the persistent left superior vena cava perpendicular to the electrode in the right ventricle. Using this configuration transvenous defibrillation was possible without an additional subcutaneous patch.     

Pain Sensation during Intradermal Injections of Three Different Botulinum Toxin Preparations in Different Doses and Dilutions

BACKGROUND: Pain sensation associated with injections of botulinum neurotoxin (BoNT) is commonly reported. To date differences in pain sensation between the commercially available products containing BoNT have not been quantified. OBJECTIVES: The pain sensations during injection of Dysport, Botox, Neurobloc, and pure saline (control) were compared. In addition, the nociceptive effect of different volumes used for the dilution of the same BoNT dose was investigated. METHODS: In a prospective, double-blind, controlled trial, 10 healthy subjects were injected intradermally with Dysport (12 U), Botox (3 and 4 U), Neurobloc (150 and 300 U) reconstituted in 0.9% saline, and pure saline. Pain sensation was quantified during injections. RESULTS: Neurobloc injections caused significantly more injection pain than Botox, Dysport, and saline. No significant differences between Dysport, Botox, and saline were found, although there was a trend toward less pain with pure saline injections. Higher pain levels with higher volumes could not be demonstrated significantly. CONCLUSION: Our data demonstrate that BoNT type B injections are associated with substantial pain. There is a considerable difference between the commercially available BoNT type B compared to the two BoNT type A preparations. Therefore, considering mitigation of injection pain seems necessary when using BoNT type B.